Antibiotic resistance surges across Europe, ECDC warns

Drug-resistant infections are spreading across Europe faster than the continent's own targets allow, new data from the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) show, with one common hospital bacterium now causing 72 per cent more bloodstream infections than in 2019.
The figures, published on 18 November to mark European Antibiotic Awareness Day and the start of World AMR Awareness Week, show Europe is behind on four of the five targets it set itself for 2030. Only the target for MRSA, a drug-resistant form of Staphylococcus aureus, is on track.
Klebsiella infections up 72 per cent
The sharpest rise concerns Klebsiella pneumoniae resistant to carbapenems, a class of antibiotics reserved for the most serious infections. Bloodstream infections caused by this bacterium were 72 per cent higher in 2025 than in 2019, rising from 2.18 to 3.75 cases per 100,000 people. The 2030 target was a 5 per cent reduction.
Infections with Escherichia coli resistant to third-generation cephalosporins, another widely used group of antibiotics, rose by 16.4 per cent over the same period, from 10.42 to 12.13 cases per 100,000 people, against a target of a 10 per cent cut. The ECDC also flagged a rise in carbapenem-resistant E. coli infections reported not only in hospitals but in the community.
There was better news on MRSA, where bloodstream infections have fallen by 19 per cent since 2019, in line with the EU target. But the ECDC warned that increases in the past two years are now threatening that progress.
Consumption barely falling
Antibiotic use itself is falling far too slowly. Total consumption in humans was 5 per cent lower in 2025 than in 2019, against a target of a 20 per cent reduction by 2030. The share of first-line antibiotics from the WHO Access group rose from 61.1 per cent to 62.5 per cent, approaching the 65 per cent target.
About 90 per cent of all human antibiotic consumption happens in the community or outpatient sector rather than in hospitals. For that reason the ECDC's 2026 campaign focuses on children, under the theme "Care for your kids - use antibiotics wisely", reminding parents that colds, coughs and sore throats are usually caused by viruses and do not need antibiotics.
ECDC Director Pamela Rendi-Wagner said Europe remained behind on several of its 2030 targets, but added that faster genomic surveillance now lets health authorities see how resistant bacteria spread and act sooner to stop transmission, guide treatment and identify where new antibiotics are most urgently needed.
First-choice drugs failing in hospitals
The WHO, which analysed the data jointly with the ECDC, warned that the situation is worse than in 2019. It found resistance to key antibiotics in at least half of the samples of Klebsiella pneumoniae and Acinetobacter in about one in two countries in Europe.
Dr Marc-Alain Widdowson, head of health security at WHO/Europe, said that in many countries in the region "the antibiotics doctors usually reach for first are failing against serious hospital infections". When those fail, doctors turn to carbapenems, and when those stop working too, he said, "what's left is mostly a small group of last-resort drugs that are often expensive and not available in every country".
The WHO also found that 16 of the 51 countries analysed still lack a standardised national approach and national coordination against antimicrobial resistance. In hospitals where few blood samples are taken, doctors often have to choose an antibiotic without knowing which one will work, the agency said.
One brighter spot was Acinetobacter, where the estimated rate of resistant bloodstream infections has almost halved since the high levels seen in 2021 during the Covid-19 pandemic.
What Europe is being asked to do
The five 2030 targets were set by a Council Recommendation adopted on 13 June 2023, using 2019 as the baseline year. Reversing the trends, the ECDC said, will require swift and sustained action, including infection prevention and control, antimicrobial stewardship, laboratory capacity and stronger surveillance.
At the point of care, the priorities are reliable hand hygiene, correct use of protective equipment, timely identification and isolation of affected patients, and effective cleaning. The ECDC has published guidance on infection prevention programmes in healthcare facilities, introduced a digital tool called hyFive to support hand-hygiene monitoring, and visited every member state between 2024 and 2026 with tailored recommendations.
More than 70 per cent of the health burden of antimicrobial resistance in the EU and European Economic Area comes from healthcare-associated infections with multidrug-resistant bacteria, about half of which could be prevented through adequate infection prevention and control, according to the ECDC.